Literature DB >> 3767346

Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.

S Czinn, H Carr, S Aronoff.   

Abstract

The presence of Campylobacter pyloridis in the gastric mucosa was recently linked to peptic ulcer disease. This study compared the inhibitory activity of three macrolide compounds (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin against 10 clinical isolates of C. pyloridis. The macrolides were equally effective against the test strains, with MICs ranging from 0.06 to 0.5 microgram/ml; rifampin was less active, with MICs ranging from 0.25 to greater than 1 microgram/ml. Erythromycin and the two new macrolide derivatives are potentially useful agents in the treatment of infections caused by C. pyloridis.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3767346      PMCID： PMC180545          DOI： 10.1128/AAC.30.2.328

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Spiral bacteria of the gastric antrum.

Authors:  C A McNulty; D M Watson
Journal:  Lancet       Date:  1984-05-12       Impact factor: 79.321

2.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

3.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

4.  Urease-positive camplyobacters.

Authors:  C R Fricker; R W Park
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

5.  Spiral organisms in endoscopic biopsies of the human stomach.

Authors:  T P Rollason; J Stone; J M Rhodes
Journal:  J Clin Pathol       Date:  1984-01       Impact factor: 3.411

6.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Campylobacter like organisms on the gastric mucosa: culture, histological, and serological studies.

Authors:  D M Jones; A M Lessells; J Eldridge
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

8.  Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy.

Authors:  A B Price; J Levi; J M Dolby; P L Dunscombe; A Smith; J Clark; M L Stephenson
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

9.  In vitro susceptibilities of Campylobacter-like organisms to twenty antimicrobial agents.

Authors:  B M Flores; C L Fennell; K K Holmes; W E Stamm
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

10.  Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.

Authors:  H Goossens; P De Mol; H Coignau; J Levy; O Grados; G Ghysels; H Innocent; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191
View more
  13 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 2.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

Authors:  J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 5.  Microbiological aspects of Helicobacter pylori (Campylobacter pylori).

Authors:  C S Goodwin; J A Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

Review 6.  Campylobacter pylori and gastroduodenal disease.

Authors:  G E Buck
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 7.  Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.

Authors:  A Burette; Y Glupczynski
Journal:  Infection       Date:  1995       Impact factor: 3.553

Review 8.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.

Authors:  G J Malanoski; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

10.  Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents.

Authors:  C A McNulty; J C Dent
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.